Stomatitis With Daraxonrasib

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have dominated clinical discussions regarding weight loss and metabolic health, but new data presented at the ASCO 2026 Annual Meeting suggest their utility may extend into the realm of oncology prophylaxis and survival.

With long-term data from the phase 3 CROWN study showing that lorlatinib (Lorbrena) can extend progression-free survival (PFS) beyond seven years in patients with ALK-positive non-small cell lung cancer (NSCLC), the focus of care is shifting from acute treatment to chronic disease management. For oncology nurses, this transition requires a proactive approach to side effect monitoring and patient counseling.

The U.S. Food and Drug Administration (FDA) has approved Cavhanza, orally disintegrating nilotinib tablets, marking a significant shift in the management of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).